TXB -Texas Biotechnology Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TXB -Texas Biotechnology

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext

To: Dave Yenne who wrote ()	11/26/1997 4:34:00 PM
From: Dave Yenne	of 19

Here is some more information on TXB: "Texas Biotechnology Corporation is developing a new generation of therapeutics focused on preserving the functional integrity of the vascular system. NOVASTAN(R) (argatroban), an injectable anticoagulant, has been submitted for approval to the FDA for heparin-induced thrombocytopenia. Texas Biotechnology is also conducting Phase II studies of its endothelin-A receptor antagonist in congestive heart failure and its selectin antagonist in asthma. Texas Biotechnology Corporation's expertise in computer-aided, small molecule drug design has generated important lead compounds for the inhibition of cell adhesion, endothelin, growth factors and programmed cell death." For the complete article go to: biz.yahoo.com Dave....

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Next 10PreviousNext